{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04602598",
            "orgStudyIdInfo": {
                "id": "58497"
            },
            "organization": {
                "fullName": "Stanford University",
                "class": "OTHER"
            },
            "briefTitle": "Zanubrutinib in Patients With IgG4-Related Disease",
            "officialTitle": "A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease",
            "therapeuticArea": [
                "Other"
            ],
            "study": "zanubrutinib-in-patients-with-related-disease"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-10-20",
            "studyFirstSubmitQcDate": "2020-10-20",
            "studyFirstPostDateStruct": {
                "date": "2020-10-26",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-20",
            "lastUpdatePostDateStruct": {
                "date": "2023-11-22",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Matthew C. Baker",
                "investigatorTitle": "Assistant Professor",
                "investigatorAffiliation": "Stanford University"
            },
            "leadSponsor": {
                "name": "Matthew C. Baker",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "Stanford University",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease",
            "detailedDescription": "This will be a single-site, open-label study in symptomatic patients with IgG4-related disease affecting the submandibular and/or lacrimal glands. All patients will receive zanubrutinib orally at a dose of 80mg BID for 24 weeks.\n\nThe primary objective of this study is to demonstrate that zanubrutinib treatment reduces reduces the volume of the submandibular and/or lacrimal glands on PET/MRI at week 24 compared to baseline."
        },
        "conditionsModule": {
            "conditions": [
                "IgG4 Related Disease"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "Open-label study in symptomatic subjects with histopathologically confirmed IgG4-related disease affecting the submandibular and/or lacrimal glands. Ten subjects will be included in the study. All eligible subjects will receive zanubrutinib 80mg BID over a period of 24 weeks and will be followed up for an additional 8 weeks after the last dose.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 10,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Zanubrutinib",
                    "type": "EXPERIMENTAL",
                    "description": "Zanubrutinib orally at a dose of 80mg BID for 24 weeks",
                    "interventionNames": [
                        "Drug: Zanubrutinib 80 MG"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Zanubrutinib 80 MG",
                    "description": "Zanubrutinib 80 MG for 24 weeks",
                    "armGroupLabels": [
                        "Zanubrutinib"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Volume of the submandibular glands on PET-MRI",
                    "description": "To demonstrate that zanubrutinib treatment reduces the volume of the submandibular glands on PET-MRI at Week 24 compared to Baseline.",
                    "timeFrame": "Baseline to Week 24"
                },
                {
                    "measure": "Volume of the lacrimal glands on PET-MRI",
                    "description": "To demonstrate that zanubrutinib treatment reduces the volume of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.",
                    "timeFrame": "Baseline to Week 24"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "FDG avidity (SUVmax) of the submandibular glands on PET-MRI",
                    "description": "Effect of zanubrutinib on change in FDG avidity (SUVmax) of the submandibular glands on PET-MRI at Week 24 compared to Baseline.",
                    "timeFrame": "Baseline to Week 24"
                },
                {
                    "measure": "FDG avidity (SUVmax) of the lacrimal glands on PET-MRI",
                    "description": "Effect of zanubrutinib on change in FDG avidity (SUVmax) of the lacrimal glands on PET-MRI at Week 24 compared to Baseline.",
                    "timeFrame": "Baseline to Week 24"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Men or women aged 18 to 85, inclusive, at the time of initial screening\n* Have histopathologically confirmed IgG4-RD in the submandibular gland and/or the lacrimal gland confirmed by international consensus pathology criteria\n\n  * Presence of a lymphoplasmacytic infiltrate with 10 IgG4+ plasma cells per high-power field and/or an IgG4+/IgG+ plasma cell ratio of 40%\n* All women must test negative for pregnancy and agree to use a reliable method of birth control\n* No current treatment with immunosuppressive medications other than prednisone 40mg daily (or other glucocorticoid equivalent) with stable dosing for 28 days\n\nExclusion Criteria:\n\n* Unstable prescribed dose of glucocorticoids within 28 days prior to baseline\n* Any treatment with a synthetic DMARD including but not limited to hydroxychloroquine, methotrexate, leflunomide, or sulfasalazine within 28 days prior to baseline\n* Any treatment with a cytotoxic or immunosuppressive drug including but not limited to cyclophosphamide, mycophenolic acid, azathioprine, cyclosporine, sirolimus, or tacrolimus within 28 days prior to baseline\n* Any treatment with a BTK inhibitor within 6 months before baseline\n* Any treatment with a JAK inhibitor within 28 days prior to baseline\n* Use of biologic agents including infliximab, abatacept, or tocilizumab within 56 days prior to baseline\n* Use of a B cell depleting therapy (such as rituximab) within 12 months prior to baseline\n* A history of, or current, inflammatory or autoimmune disease (that could affect the interpretation of safety or efficacy outcomes) other than IgG4-related disease\n* Evidence of active tuberculosis, HIV, or hepatitis B or C infection\n* History of cancer other than non-melanoma skin cancer, cervical dysplasia or carcinoma in situ (cured \\>1 year), prostate cancer (cured \\>5 years), or colon cancer (cured \\>5 years)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "85 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Matthew C Baker, MD",
                    "role": "CONTACT",
                    "phone": "650-497-0774",
                    "email": "mbaker13@stanford.edu"
                },
                {
                    "name": "Angie R Aberia, BA",
                    "role": "CONTACT",
                    "phone": "650-723-8516",
                    "email": "aaberia@stanford.edu"
                }
            ],
            "locations": [
                {
                    "facility": "Stanford University",
                    "status": "RECRUITING",
                    "city": "Palo Alto",
                    "state": "California",
                    "zip": "94304",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Matthew C Baker, MD, MS",
                            "role": "CONTACT"
                        },
                        {
                            "name": "Matthew C Baker, MD, MS",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.44188,
                        "lon": -122.14302
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000077733",
                    "term": "Immunoglobulin G4-Related Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M1891",
                    "name": "Immunoglobulin G4-Related Disease",
                    "asFound": "IgG4-related Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3010",
                    "name": "IgG4-related Disease",
                    "asFound": "IgG4-related Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3927",
                    "name": "Multifocal Fibrosclerosis",
                    "asFound": "IgG4-related Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000629551",
                    "term": "Zanubrutinib"
                }
            ],
            "ancestors": [
                {
                    "id": "D000092004",
                    "term": "Tyrosine Kinase Inhibitors"
                },
                {
                    "id": "D000047428",
                    "term": "Protein Kinase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M42199",
                    "name": "Zanubrutinib",
                    "asFound": "Flavor",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2889",
                    "name": "Tyrosine Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M25820",
                    "name": "Protein Kinase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "T22",
                    "name": "Tyrosine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AA",
                    "name": "Amino Acids"
                }
            ]
        }
    },
    "hasResults": false
}